Table 2.
Genotypic and allelic frequencies of PCOS susceptible gene polymorphisms
| Cases | Control | χ2 (P) | HWE χ2 (P) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| Genotype % (n) | Allele % | Genotype % (n) | Allele % | |||||||
| DENND1A (rs10818854) | GG | 90 (18) | G | 95 | GG | 100 (10) | G | 100 | 13.76 (0.001*) | 2.065 (0.356) |
| GA+AA | 10 (2) | A | 5 | GA+GG | 0 (0) | A | 0 | |||
| LHCGR (rs13405728) | AA | 50 (10) | A | 75 | AA | 50 (5) | A | 75 | 1.667 (0.197) | 2.297 (0.130) |
| AG+GG | 50 (10) | G | 25 | AG+GG | 50 (5) | G | 25 | |||
| THADA (rs13429458) | AA | 80 (16) | A | 90 | AA | 80 (8) | A | 85 | 1.071 (0.301) | 1.154 (0.183) |
| AC+CC | 20 (4) | C | 10 | AC+CC | 20 (2) | C | 15 | |||
| FSHR (rs2349415) | AA | 10 (2) | A | 40 | AA | 0 (0) | A | 15 | 2.857 (0.091) | 11.627 (0.001*) |
| AG+GG | 90 (18) | G | 60 | AG+GG | 100 (10) | G | 85 | |||
| CX37 (rs1764391) | CC | 70 (14) | C | 82.5 | CC | 50 (5) | C | 70 | 2.500 (0.114) | 8.64 (0.003*) |
| CG+GG | 30 (6) | G | 17.5 | CG+GG | 50 (5) | G | 30 | |||
| ACEI/D (rs1799752) | II | 30 (6) | I | 57.5 | II | 10 (1) | I | 25 | 3.333 (0.504) | 1.568 (0.457) |
| ID | 55 (11) | D | 42.5 | ID | 30 (3) | D | 75 | |||
| DD | 15 (3) | DD | 60 (6) | |||||||
| INSR (rs1799817) | CC | 45 (9) | C | 70 | CC | 20 (2) | C | 45 | 2.222 (0.329) | 12.150 (0.001*) |
| CT+TT | 55 (11) | T | 30 | CT+TT | 80 (8) | T | 55 | |||
| CAPN10 (rs2975760) | TT | 65 (13) | T | 82.5 | TT | 80 (8) | T | 90 | 1.071 (0.301) | 1.875 (0.171) |
| TC+CC | 35 (7) | C | 17.5 | TC+CC | 20 (2) | C | 10 | |||
*Significant at P<0.05; χ2: Pearson’s Chi-square test to assess the relative association between the patients and controls for genotype and allele frequencies; HWE χ2 indicates the result from the Hardy-Weinberg distribution of genotypes in the PCOS and control groups; DENND1A - DENN domain containing 1A; LHCGR - Luteinizing hormone/chorionic gonadotropin receptor. FSHR - follicle-stimulating hormone receptor; CX37 - Connexin37; ACE I/D - Angiotensin-converting enzyme insertion/deletion polymorphism; INSR - Insulin receptor; CAPN10 - Calpain-10